Debjit Chattopadhyay

Roth Capital analyst Debjit Chattopadhyay weighed in today with a favorable report on bluebird bio Inc (NASDAQ:BLUE), reiterating a Buy rating and $192 price target, which implies …

Roth Capital’s healthcare analyst Debjit Chattopadhyay weighed in today with his views on Cempra Inc (NASDAQ:CEMP), following the news that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)’s IGNITE2 phase …

Roth Capital analyst Debjit Chattopadhyay issued a note to investors on August 25 highlighting the recent stock market drop. However, the analyst found …

In a research report published Wednesday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on shares of Cempra Inc (NASDAQ:CEMP) with a price …

Roth Capital analyst Debjit Chattopadhyay weighed in today with a few insights on Sarepta Therapeutics Inc (NASDAQ:SRPT), following the news that Sprout’s Flibanserin was approved as …

Roth Capital analyst Debjit Chattopadhyay weighed in with a few insights on CTI BioPharma Corp (NASDAQ:CTIC), after the company reported its second-quarter results and outlined its …

On August 2, Roth Capital analyst Debjit Chattopadhyay published a report providing a list of upcoming catalysts for several biotechnology companies including Sarepta Therapeutics Inc (NASDAQ:SRPT), Bluebird Bio Inc (NASDAQ:BLUE), and Agios …

On August 2, Roth Capital analyst Debjit Chattopadhyay published a report providing a list of upcoming catalysts for several biotechnology companies including Sarepta Therapeutics Inc (NASDAQ:SRPT),Bluebird Bio Inc (NASDAQ:BLUE), and Agios Pharmaceuticals …

With Cempra Inc (NASDAQ:CEMP) preparing to release second-quarter earnings tomorrow after market close, Roth Capital analyst Debjit Chattopadhyay weighed in today with a …

Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Sarepta Therapeutics Inc (NASDAQ:SRPT) Monday, reiterating a Buy rating and price target of $45, …